Quest Diagnostics (DGX) was upgraded to Zacks Rank #2 (Buy), signaling improved earnings expectations and a more favorable near-term outlook. The note is positive for the stock, but it is an analyst-rating update rather than a fundamental operating announcement, so the likely market impact is limited.
Quest Diagnostics (DGX) was upgraded to Zacks Rank #2 (Buy), signaling improved earnings expectations and a more favorable near-term outlook. The note is positive for the stock, but it is an analyst-rating update rather than a fundamental operating announcement, so the likely market impact is limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
